12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Company News  |  Deals

Ironwood, AstraZeneca deal

Ironwood partnered with AstraZeneca to co-develop and co-commercialize the biotech's linaclotide in China. In May, Ironwood submitted an application in China to begin a Phase III trial of linaclotide to treat irritable bowel syndrome with...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >